tm logo
AYRESVY
REGISTERED

on 24 May 2023

Last Applicant/ Owned by

GLAXOSMITHKLINE BIOLOGICALS SA

Rue de I'Institut 89Rixensart, B-1330

BE

Serial Number

2197260 filed on 12th Jul 2022

Registration Number

TMA1182080 registered on 24th May 2023

Registration expiry Date

24th May 2033

Correspondent Address

1, Place Ville MarieSuite 2500, Montreal

QUEBEC

CA

H3B1R1

AYRESVY

Trademark usage description

allergy medications; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thy Read More

Classification Information


Class [005]
Allergy medications; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of disorders of the respiratory system; pharmaceutical preparations for the prevention and treatment of iron deficiency and anemia in humans; pharmaceutical preparations for the prevention and treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the prevention and treatment of renal disease and disorders; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; pharmaceutical preparations for the treatment and prevention of hiv infection; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections.; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders namely irritable bowel disorders and symptoms; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrheal and infertility; pharmaceutical preparations for the treatment of hepatitis; pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone, androgen and estrogen disorders; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely polycystic ovary syndrome; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of sexual dysfunction; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system namely brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of tuberculosis; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating digestive system disorders; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for use in hematology, namely for the treatment of blood disorders; pharmaceutical preparations for use in ophthalmology; vaccines namely prophylactic and therapeutic vaccines for humans


Classification kind code

11

Mark Details


Serial Number

2197260

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 190
on 24th May 2023
Registration Pending
Submitted for opposition 55
on 24th May 2023
Registered
Submitted for opposition 42
on 22nd Feb 2023
Advertised
Submitted for opposition 26
on 27th Jan 2023
Approved
Submitted for opposition 27
on 27th Jan 2023
Approval Notice Sent
Submitted for opposition 22
on 23rd Jan 2023
Search Recorded
Submitted for opposition 30
on 12th Jul 2022
Filed
Submitted for opposition 1
on 12th Jul 2022
Created
Submitted for opposition 31
on 12th Jul 2022
Formalized